Zimmer Biomet Holdings (ZBH) : Analyst Rating Update

Zimmer Biomet Holdings (ZBH) has an average broker rating of 1.7, which is interpreted as a Buy, as rated by 22 equity analysts. Nonetheless, 13 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Zimmer Biomet Holdings (ZBH) : 14 Wall Street analysts covering Zimmer Biomet Holdings (ZBH) believe that the average level the stock could reach for the short term is $129. The maximum price target given is $135 and the minimum target for short term is around $105, hence the standard deviation is calculated at $8.34.

Zimmer Biomet Holdings (NYSE:ZBH): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $119.82 and $119.33 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $121.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $121.78, notching a gain of 1.53% for the day. The total traded volume was 1,837,830 . The stock had closed at $119.95 on the previous day.

Also, Guggenheim Securities initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH) The current rating of the shares is Neutral. The rating by the firm was issued on June 9, 2016.

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.